(RTTNews) - Pharming Group N.V. (PHGUF.PK, PHGUF.OB, PHAR, PHARM.AS), a Netherlands-based biotechnology company focused on rare immune and genetic diseases, on Thursday reported increased preliminary revenue for the third quarter of fiscal 2026, driven by higher revenue from its
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.